Autolus Therapeutics Announces FDA Approval of AUCATZYL®

obe-cel) for adults with relapsed/refractory B-cell acute ...

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell ...

FDA approves obecabtagene autoleucel for adults with relapsed or ...

On November 8, 2024, the Food and Drug Administration approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-directed genetically modified ...

Autolus enters CAR-T race with FDA approval for Aucatzyl

Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy arena ...

UCL spinout Autolus gains US approval for cancer therapy

Autolus Therapeutics, a UCL spinout company, has received U.S. Food and Drug Administration (FDA) approval, for a next-generation CAR-T cell ...

Autolus Therapeutics announces FDA approval of AUCATZYL

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy); ...

FDA Approves Autolus' Aucatzyl for Relapsed/Refractory B-Cell ...

The FDA has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel or obe-cel), a chimeric antigen receptor T-cell therapy for ...

FDA approves new CAR-T competitor to Gilead's Tecartus

The Food and Drug Administration on Friday approved a new cell therapy for a type of leukemia. · Aucatzyl will compete with Gilead Sciences' ...

Autolus Therapeutics announces FDA Approval of AUCATZYL ...

Autolus Therapeutics announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute ...

Autolus secures FDA approval for CAR-T cell therapy use in ALL

Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy (REMS) programme.

FDA Approves Obe-Cel for Adults With R/R B-Cell Precursor Acute ...

The FDA announced that is has approved obecabtagene autoleucel (Aucatzyl; Autolus Inc), known colloquially as obe-cel, a CD19-directed ...

Autolus Therapeutics announces FDA approval of Aucatzyl

On November 8, the US Food and Drug Administration approved Aucatzyl (obecabtagene autoleucel; obe-cel) from US biopharma Autolus ...

Geraint Rees on LinkedIn: Autolus Therapeutics announces FDA ...

Great to see this new treatment developed by UCL's spinout Autolus achieving FDA approval and so now able to benefit patients (in the US)!

Autolus Therapeutics announces FDA approval of Aucatzyl - Nasdaq

Autolus Therapeutics (AUTL) announces the U.S. FDA has granted marketing approval for Aucatzyl for the treatment of adult patients with ...

Autolus receives US FDA approval – Company Announcement

AUCATZYL was approved by the FDA for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ...

Autolus Therapeutics Reports Third Quarter 2024 Financial Results ...

Autolus Therapeutics announces FDA approval of AUCATZYL® (obecabtagene autoleucel) for adult B-cell Acute Lymphoblastic Leukemia treatment, ...

New CAR T-cell therapy approved by FDA for adult ALL

The US Food and Drug Administration (FDA) has approved Autolus Therapeutics' Aucatzyl (obecabtagene autoleucel) to treat acute lymphoblastic leukemia (ALL).

Press Releases | Autolus Therapeutics plc

Nov 08, 2024. Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute ...

Autolus Therapeutics Announces FDA Approval of AUCATZYL ...

AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy)Approval ...

FDA Approves Obecabtagene Autoleucel for Relapsed/Refractory B ...

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for the treatment of adult patients with relapsed or refractory B-cell precursor ...

Fengqian Chen, Ph.D. on LinkedIn: Autolus Therapeutics ...

Fengqian Chen, Ph.D.'s Post · Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with ...